Prescient Therapeutics Moves Advanced PTX-100 Cutaneous T-Cell Lymphoma Therapy Closer to Commercialisation
Prescient Therapeutics (ASX: PTX) is fast emerging as the newest developer of an advanced cancer drug...
Prescient Therapeutics (ASX: PTX) is fast emerging as the newest developer of an advanced cancer drug...
Oncology biotech Prescient Therapeutics (ASX: PTX) has announced the completion of its first US site visit for...
In this exclusive interview, Jess Fertig hosts James McDonnell, CEO of Prescient Therapeutics (ASX: PTX),...
In this exclusive interview, Jess Fertig hosts James McDonnell, CEO of Prescient Therapeutics (ASX: PTX),...
Clinical-stage oncology company Prescient Therapeutics (ASX: PTX) is looking to disrupt a US$1.8 billion market on the...
Prescient Therapeutics (ASX: PTX) has received fast-track designation from the US Food and Drug Administration...
Australian clinical stage oncology company Prescient Therapeutics (ASX: PTX) is set to present the exciting results from...
Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has reported a solid end to financial year 2023...
Clinical stage oncology company Prescient Therapeutics (ASX: PTX) will present two of its abstracts at an annual...
Prescient Therapeutics (ASX: PTX) managing director and chief executive officer Steven Yatomi-Clarke joins Small Caps...

This investor centre was built by Reach Markets
©2026 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.